Potential therapeutic role of statins in neurological disorders

References

• Ginsberg HN. Effects of statins on triglyceride metabolism. Am. J. Cardiol.81, 32B–35B (1998).
   PubMedGoogle Scholar
• Liao JK, Laufs U. Pleiotropic effects of statins. Ann. Rev. Pharmacol. Toxicol.45, 89–118 (2005).
   PubMed Web of Science ®Google Scholar
• Krysiak R, Okopien B, Herman Z. Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. Drugs63, 1821–1854 (2003).
   PubMed Web of Science ®Google Scholar
• Shechter M, Beigel R, Matetzky S, Freimark D, Chouraqui P. The intensive statin therapy myth. Isr. Med. Assoc. J.7, 683–687 (2005).
   PubMedGoogle Scholar
• Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature343, 425–430 (1990).
   PubMed Web of Science ®Google Scholar
• Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler. Thromb. Vasc. Biol.21, 1712–1719 (2001).
   PubMed Web of Science ®Google Scholar
• Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation109(Suppl 1), III39–III43 (2004).
   PubMed Web of Science ®Google Scholar
• Van Aelst L, D’Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev.11, 2295–2322 (1997).
   PubMed Web of Science ®Google Scholar
• Hall A. Rho GTPases and the actin cytoskeleton. Science279, 509–514 (1998).
   PubMed Web of Science ®Google Scholar
• Endres M, Laufs U. Effects of statins on endothelium and signaling mechanisms. Stroke35(Suppl. 1), 2708–2711 (2004).
   PubMed Web of Science ®Google Scholar
• John S, Delles C, Jacobi J et al. Rapid improvement of nitric oxide bioavailability after lipid lowering therapy with cerivastatin within two weeks. J. Am. Coll. Cardiol.37, 1351–1358 (2001).
   PubMed Web of Science ®Google Scholar
• O’Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation95, 1126–1131 (1997).
   PubMed Web of Science ®Google Scholar
• Mason RP, Walter MF, Jacob RF. Effects of HMG-CoA reductase inhibitors on endothelial function: role of microdomains and oxidative stress. Circulation109(Suppl. 1), II34–II41 (2004).
   PubMedGoogle Scholar
• Cucchiara B, Kasner SE. Use of statins in CNS disorders. J. Neurol. Sci.187, 81–89 (2001).
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang ZG, Ding GL et al. Multitargeted effects of statin-enhanced thrombolytic therapy for stroke with recombinant human tissue-type plasminogen activator in the rat. Circulation112, 3486–3494 (2005).
   PubMed Web of Science ®Google Scholar
• Sparks DL, Sabbagh MN, Connor DJ et al. Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD. Curr. Alzheimer Res.2, 343–353 (2005).
   PubMedGoogle Scholar
• Steinman L. Immune therapy for autoimmune diseases. Science305, 212–216 (2004).
   PubMed Web of Science ®Google Scholar
• Youssef S, Stüve O, Patarroyo JC et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature420, 78–84 (2002).
   PubMed Web of Science ®Google Scholar
• Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat. Med.6, 1399–1402 (2000).
   PubMed Web of Science ®Google Scholar
• Neuhaus O, Strasser-Fuchs S, Fazekas F et al. Statins as immunomodulators: comparison with interferon-β 1b in MS. Neurology59, 990–997 (2002).
   PubMed Web of Science ®Google Scholar
• Aktas O, Waiczies S, Smorodchenko A et al. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J. Exp. Med.197, 725–733 (2003).
   PubMed Web of Science ®Google Scholar
• Greenwood J, Walters CE, Pryce G et al. Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB J.17, 905–907 (2003).
   PubMed Web of Science ®Google Scholar
• Nath N, Giri S, Prasad R et al. Potential targets of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy. J. Immunol.172, 1273–1286 (2004).
   PubMed Web of Science ®Google Scholar
• Ganné F, Vasse M, Beaudeux JL et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits urokinase/urokinasereceptor expression and MMP-9 secretion by peripheral blood monocytes a possible protective mechanism against atherothrombosis. Thromb. Haemost.84, 680–688 (2000).
   PubMedGoogle Scholar
• Dunn SE, Youssef S, Goldstein MJ et al. Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J. Exp. Med.203(2), 401–412 (2005).
   Google Scholar
• Jorritsma PJ, Brogdon JL, Bottomly K et al. Role of TCR-induced extracellular signal-regulated kinase activation in the regulation of early IL-4 expression in naive CD4+ T cells. J. Immunol.170, 2427–2434 (2003).
   PubMed Web of Science ®Google Scholar
• Liao JK. Role of statin pleiotropism in acute coronary syndromes and stroke. Int. J. Clin. Pract. (Suppl. 134), 51–57 (2003).
   Google Scholar
• Li JJ, Chen XJ. Simvastatin inhibits interleukin-6 release in human monocytes stimulated by C-reactive protein and lipopolysaccharide. Coron. Artery Dis.14, 329–334 (2003).
   PubMedGoogle Scholar
• Waehre T, Damas JK, Gullestad L et al. Hydroxymethyl glutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in subjects with coronary artery disease. J. Am. Coll. Cardiol.41, 1460–1467 (2003).
   PubMed Web of Science ®Google Scholar
• Waehre T, Yndestad A, Smith C et al. Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors. Circulation109, 1966–1972 (2004).
   PubMed Web of Science ®Google Scholar
• Rezaie-Majd A, Maca T, Bucek RA et al. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler. Thromb. Vasc. Biol.22, 1194–1199 (2002).
   PubMed Web of Science ®Google Scholar
• Devaraj S, Chan E, Jialal I. Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome J. Clin. Endocrinol. Metab.91(11), 4489–4496 (2006).
   Google Scholar
• Weis M, Heeschen C, Glassford AJ, Cooke JP. Statins have biphasic effects on angiogenesis. Circulation105, 739–745 (2002).
   PubMed Web of Science ®Google Scholar
• Llevadot J, Murasawa S, Kureishi Y et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J. Clin. Invest.108, 399–405 (2001).
   PubMed Web of Science ®Google Scholar
• Spyridopoulos I, Haendeler J, Urbich C et al. Statins enhance migratory capacity by upregulation of the telomere repeat-binding factor TRF2 in endothelial progenitor cells. Circulation110, 3136–3142 (2004).
   PubMed Web of Science ®Google Scholar
• Dimmeler S, Aicher A, Vasa M et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J. Clin. Invest.108, 391–397 (2001).
   PubMed Web of Science ®Google Scholar
• Assmus B, Urbich C, Aicher A et al. HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. Circ. Res.92, 1049–1055 (2003).
   PubMed Web of Science ®Google Scholar
• Kureishi Y, Luo Z, Shiojima I et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat. Med.6, 1004–1010 (2000).
   PubMed Web of Science ®Google Scholar
• Nakao T, Shiota M, Tatemoto Y, Izumi Y, Iwao H. Pravastatin induces rat aortic endothelial cell proliferation and migration via activation of PI3K/Akt/mTOR/p70 S6 kinase signaling. J. Pharmacol. Sci.105(4), 334–341 (2007).
   PubMedGoogle Scholar
• Muck AO, Seeger H, Wallwiener D. Class-specific pro-apoptotic effect of statins on human vascular endothelial cells. Z. Kardiol.93, 398–402 (2004).
   PubMedGoogle Scholar
• Kaneta S, Satoh K, Kano S, Kanda M, Ichihara K. All hydrophobic HMG-CoA reductase inhibitors induce apoptotic death in rat pulmonary vein endothelial cells. Atherosclerosis170, 237–243 (2003).
   PubMed Web of Science ®Google Scholar
• Rikitake Y, Liao JK. Rho GTPases, statins, and nitric oxide. Circ. Res.97, 1232–1235 (2005).
   PubMed Web of Science ®Google Scholar
• Brown JH, Del Re DP, Sussman MA. The Rac and Rho hall of fame: a decade of hypertrophic signaling hits. Circ. Res.98, 730–742 (2006).
   PubMed Web of Science ®Google Scholar
• Chenevard R, Hurlimann D, Bechir M et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation107, 405–409 (2003).
   PubMed Web of Science ®Google Scholar
• Deng P, Zhao SP, Wu J et al. Atorvastatin reduces the expression of COX-2 mRNA in peripheral blood monocytes from patients with acute myocardial infarction and modulates the early inflammatory response. Zhonghua Xin Xue Guan Bing Za Zhi33(11), 1018–1022 (2005).
   PubMedGoogle Scholar
• Hernandez-Presa MA, Martin-Ventura JL, Ortego M et al. Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. Atherosclerosis160, 49–58 (2002).
   PubMedGoogle Scholar
• Inoue I, Itoh F, Aoyagi S et al. Fibrate and statin synergistically increase the transcriptional activities of PPARα/RXα and decrease the transactivation of NFκB. Biochem. Biophys. Res. Commun.290, 131–139 (2002).
   PubMedGoogle Scholar
• Eto M, Kozai T, Cosentino F, Joch H, Luscher TF. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation105, 1756–1759 (2002).
   PubMed Web of Science ®Google Scholar
• Bourcier T, Libby P. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler. Thromb. Vasc. Biol.20, 556–562 (2000).
   PubMed Web of Science ®Google Scholar
• Essig M, Nguyen G, Prie D, Escoubet B, Sraer JD, Friedlander G. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins. Circ. Res.83, 683–690 (1998).
   PubMedGoogle Scholar
• Dangas G, Smith DA, Unger AH et al. Pravastatin: an antithrombotic effect independent of the cholesterol-lowering effect. Thromb. Haemost.83, 688–692 (2000).
   PubMed Web of Science ®Google Scholar
• Wayman NS, Ellis BL, Thiemermann C. Simvastatin reduces infarct size in a model of acute myocardial ischemia and reperfusion in the rat. Med. Sci. Monit.9, BR155–BR159 (2003).
   PubMedGoogle Scholar
• Matsuki A, Igawa A, Nozawa T et al. Early administration of fluvastatin, but not at the onset of ischemia or reperfusion, attenuates myocardial ischemia-reperfusion injury through the nitric oxide pathway rather than its antioxidant property. Circ. J.70, 1643–1649 (2006).
   PubMedGoogle Scholar
• Wolfrum S, Dendorfer A, Schutt M et al. Simvastatin acutely reduces myocardial reperfusion injury in vivo by activating the phosphatidylinositide 3-kinase/ Akt pathway. J. Cardiovasc. Pharmacol.44, 348–355 (2004).
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Minatoguchi S, Hashimoto Y et al. Role of protein kinase C, KATP channels and DNA fragmentation in the infarct size-reducing effect of the free radical scavenger T-0970. Clin. Exp. Pharmacol. Physiol.28, 193–199 (2001).
   PubMed Web of Science ®Google Scholar
• Bao N, Minatoguchi S, Kobayashi H et al. Pravastatin reduces myocardial infarct size via increasing protein kinase C-dependent nitric oxide, decreasing oxyradicals and opening the mitochondrial adenosine triphosphate-sensitive potassium channels in rabbits Circ. J.71, 1622–1628 (2007).
   PubMed Web of Science ®Google Scholar
• Biccard BM, Sear JW, Foex P. Statin therapy: a potentially useful peri-operative intervention in patients with cardiovascular disease. Anaesthesia60, 1106–1114 (2005).
   PubMedGoogle Scholar
• Sever PS, Poulter NR, Daholf B, Wedel H. Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo–Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA). Am. J. Cardiol.96(5A), 39F–44F (2005).
   PubMed Web of Science ®Google Scholar
• Elrod JW, Lefer DJ. The effects of statins on endothelium, inflammation and cardioprotection. Drugs News Perspect.18, 229–236 (2005).
   PubMedGoogle Scholar
• Arnaud C, Mach F. Pleiotropic effects of statins in atherosclerosis: role on endothelial function, inflammation and immunomodulation. Arch. Mal. Coeur. Vaiss.98, 661–666 (2005).
   PubMedGoogle Scholar
• Kagan A, Popper JS, Rhoads GG. Factors related to stroke incidence in Hawaii Japanese men. The Honolulu Heart Study. Stroke11(1), 14–21 (1980).
   PubMed Web of Science ®Google Scholar
• Salonen JT, Puska P, Tuomiletho J, Homan K. Relation of blood pressure, serum lipids, and smoking to the risk of cerebral stroke. A longitudinal study in Eastern Finland. Stroke13(3), 327–333 (1982).
   PubMed Web of Science ®Google Scholar
• Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 Prospective cohorts. Prospective studies collaboration. Lancet346(8991–8992), 1647–1653 (1995).
   PubMed Web of Science ®Google Scholar
• Iso H, Jacobs DR Jr, Wentworth D, Neaton JD. Serum cholesterol levels and six-year mortality from stroke 350,977 men screened for the multiple risk factor intervention trial. N. Engl. J. Med.320(14), 904–910 (1989).
   PubMed Web of Science ®Google Scholar
• Armani A, Toth PP. SPARCL: the glimmer of statins for stroke risk reduction. Curr. Atheroscler. Rep.9(5), 347–351 (2007).
   PubMedGoogle Scholar
• Colivicchi F, Bassi A, Santini M, Caltagirone C. Discontinuation of statin therapy and clinical outcome after ischemic stroke. Stroke38(10), 2652–2657 (2007).
   PubMed Web of Science ®Google Scholar
• Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Blood pressure, cholesterol, and stroke in eastern Asia. Lancet352(9143), 1801–1807 (1998).
   PubMedGoogle Scholar
• Yano K, Reed DM, Maclean CJ. Serum cholesterol and hemorrhagic stroke in the Honolulu Heart program. Stroke20, 1460–1465 (1989).
   PubMed Web of Science ®Google Scholar
• Heart protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet360, 7–22 (2002).
   PubMed Web of Science ®Google Scholar
• Lynch JR, Wang H, McGirt MJ. Simvastatin reduces vasospasm after aneurysmal subarachnoid hemorrhage: results of a pilot randomized clinical trial. Stroke36, 2024–2026 (2005).
   PubMed Web of Science ®Google Scholar
• Fuster V, Badimon L, Badimon JJ. The pathogenesis of coronary heart disease and the acute coronary syndromes (2). N. Engl. J. Med.326(5), 310–318 (1992).
   PubMed Web of Science ®Google Scholar
• Bellosta S, Via D, Canavesi M et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler. Thromb. Vasc. Biol.18(11), 1671–1678(1998).
   PubMed Web of Science ®Google Scholar
• Sakai M, Kobori S, Matsumura T et al. HMG-CoA reductase inhibitors suppress macrophages growth induced by oxidized low density lipoprotein. Atherosclerosis133(1), 51–59 (1997).
   PubMed Web of Science ®Google Scholar
• Igarashi M, Takeda Y, Mori S et al. Suppression of neointimal thickening by a newly developed HMG-CoA reducatase inhibitor, BAYw6128, and its inhibitory effect on vascular smooth muscle cell growth. Br. J. Pharmacol.120(6), 1172–1178 (1997).
   PubMed Web of Science ®Google Scholar
• Llorente-Cortes V, Martinez-Gonzalez J, Badimon L. Esterified cholesterol accumulation induced by aggregated LDL uptake in human vascular smooth muscle cells is reduced by HMG-CoA reducatase inhibitors. Arterioscler. Thromb. Vasc. Biol.18(5), 738–746 (1998).
   PubMedGoogle Scholar
• Notarbartolo A, Davi G, Averna M et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol.15(2), 247–251 (1995).
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Tngney CC. Antiatherothrombotic properties of statins: implications for cardiovascular events reduction. JAMA279(20), 1643–1650 (1998).
   PubMed Web of Science ®Google Scholar
• Clark RS, Kochanek PM, Schwarz MA et al. Inducible nitric oxide synthase expression in cerebrovascular smooth muscle and nutrophils after traumatic brain injury in immature rats. Pediatr. Res.39(5), 784–790 (1996).
   PubMed Web of Science ®Google Scholar
• Vaughan CJ, Delanty N. Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke30(9), 1969–1973 (1999).
   PubMed Web of Science ®Google Scholar
• Chan PH. Role of oxidants in ischemic brain damage. Stroke27(6), 1124–1129 (1996).
   PubMed Web of Science ®Google Scholar
• Prince M, Cullen M, Mann A. Risk factors for Alzheimer’s disease and dementia: a case control study based on the MRC elderly hypertension trial. Neurology44(1), 97–104 (1994).
   PubMedGoogle Scholar
• Sparks DL. Intraneuronal b-amyloid immunoreactivity in the CNS. Neurobiol. Aging17(2), 291–299 (1996).
   PubMed Web of Science ®Google Scholar
• Kamboh MI, Ferrell RE, DeKosky ST. Genetic association studies between Alzheimer’s disease and two polymorphisms in the low density lipoprotein receptor-related protein gene. Neurosci. Lett.244(2), 65–68 (1998).
   PubMed Web of Science ®Google Scholar
• Mitchel YB, Kramer MS, Matzura-Wolfe DM et al. The effect of simvastatin on cerebrospinal fluid levels of apolipoprotein E in patients with Alzheimer’s disease [abstract]. Atherosclerosis115, S113 (1995).
   Google Scholar
• Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer’s disease associated with 3-HMG-CoA reductase inhibitors. Arch. Neurol.57, 1439–1443 (2000).
   PubMed Web of Science ®Google Scholar
• Jick H, Zornberg GL, Jick SS, Sehadri S. Statins and the risk of dementia. Lancet356, 1627–1631 (2000).
   PubMed Web of Science ®Google Scholar
• Wardle J, Rogers P, Judd P et al. Randomized trial of the effects of cholesterol-lowering dietary treatment on psychological function. Am. J. Med.108(7), 547–553 (2000).
   PubMed Web of Science ®Google Scholar
• Shults CW. Therapeutic role of coenzyme Q(10) in Parkinson’s disease. Pharmacological Ther.107, 120–130 (2005).
   PubMed Web of Science ®Google Scholar
• Selley ML. Simvastatin prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced striatal dopamine depletion and protein tyrosine nitration in mice. Brain Res.1037, 1–6 (2005).
   PubMed Web of Science ®Google Scholar
• Kobashigawa JA, Katznelson S, Laks H et al. Effect of pravastatin on outcomes after cardiac transplantation. N. Engl. J. Med.333, 621–627 (1995).
   PubMed Web of Science ®Google Scholar
• Cutts JL, Scalle TJ, Watson J, Bankhurst AD. Role of mevalonic acid in the regulation of natural killer cell cytotoxicity. J. Cell Physiol.139, 550–557 (1989).
   PubMed Web of Science ®Google Scholar
• Pruefer D, Scalia R, Lefer AM. Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats. Arterioscler. Thromb. Vasc. Biol.19, 2894–2900 (1999).
   PubMed Web of Science ®Google Scholar
• Wagner AH, Gebauer M, Guldenzoph B. 3-hydroxy-3-methylglutaryl coenzyme A reductase-independent inhibition of CD40 expression by atorvastatin in human endothelial cells. Arterioscler. Thromb. Vasc. Biol.22, 1784–1789 (2002).
   PubMedGoogle Scholar
• Pahan K, Sheikh FG, Namboodiri AM, Singh I. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J. Clin. Invest.100, 2671–2679 (1997).
   PubMed Web of Science ®Google Scholar
• Stanislaus R, Pahan K, Singh AK, Singh I. Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin. Neurosci. Lett.269, 71–74 (1999).
   PubMed Web of Science ®Google Scholar
• Aktas O, Waiczies S, Smorodchenko A. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J. Exp. Med.197, 725–733 (2003).
   PubMed Web of Science ®Google Scholar
• Vollmer T, Key L, Durkalski V, Tyor W. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet363, 1607–1608 (2004).
   PubMed Web of Science ®Google Scholar
• Birnbaum G, Altafullah I. A double blind, placebo controlled combination trial of interferon β 1a (Rebif) and atorvastatin (lipitor) in patients with relapsing remitting multiple sclerosis. Presented at: Proceedings of the 57th meeting of the American Academy of Neurology. Miami Beach, FL, USA, 9–16 April 2005.
   Google Scholar
• Soma MR, Baetta R, De Renzis MR et al.in vivo enhanced antitumor activity of carmustine by simvastatin. Cancer Res.55, 597–602 (1995).
   PubMed Web of Science ®Google Scholar
• Macaulay RJ, Wang W, Dimitroulakos J, Becker LE, Yeger H. Lovastatin-induced apoptosis of human medulloblastoma cell lines in vitroJ. Neurooncol.42(1), 1–11 (1999).
   PubMed Web of Science ®Google Scholar
• Jukema JW, Bruschke AV, van Boven AJ et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: The regression Growth evaluation Statin Study (REGRESS). Circulation292, 2528–2540 (1995).
   Google Scholar
• Staffa JA, Chang J, Green L. Cerivastastin and reports of fatal rhabdomyolysis. N. Engl. J. Med.346, 539–540 (2002).
   PubMed Web of Science ®Google Scholar
• Gaist D, Jeppesen U, Andersen M, García Rodríguez LA, Hallas J, Sindrup SH. Statins and risk of polyneuropathy: a case control study. Neurology58, 1333–1337 (2002).
   PubMed Web of Science ®Google Scholar